UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Toward personalized treatment approaches for non-small-cell lung cancer

Nature medicine, 2021-08, Vol.27 (8), p.1345-1356

2021

Volltextzugriff (PDF)

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC

Nature reviews. Clinical oncology, 2021-10, Vol.18 (10), p.625-644

2021

Volltextzugriff (PDF)

Lung cancer in the era of precision medicine

Clinical cancer research, 2015-05, Vol.21 (10), p.2213-2220

2015

Volltextzugriff (PDF)

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes

Clinical cancer research, 2019-08, Vol.25 (15), p.4592-4602

2019

Volltextzugriff (PDF)

Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer

Clinical cancer research, 2016-08, Vol.22 (15), p.3713-3717

2016

Volltextzugriff (PDF)

To kill a tumor cell: the potential of proapoptotic receptor agonists

The Journal of clinical investigation, 2008-06, Vol.118 (6), p.1979-1990

2008

Volltextzugriff (PDF)

Objective measurement and clinical significance of TILs in non-small cell lung cancer

JNCI : Journal of the National Cancer Institute, 2015-03, Vol.107 (3), p.1

2015

Volltextzugriff (PDF)

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

Clinical cancer research, 2018-04, Vol.24 (8), p.1872-1880

2018

Volltextzugriff (PDF)

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Nature (London), 2014-11, Vol.515 (7528), p.563-567

2014

Volltextzugriff (PDF)

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

The Lancet (British edition), 2016-04, Vol.387 (10027), p.1540-1550

2016

Volltextzugriff (PDF)

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

Clinical cancer research, 2019-08, Vol.25 (15), p.4663-4673

2019

Volltextzugriff (PDF)

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer

Clinical cancer research, 2018-04, Vol.24 (7), p.1562-1573

2018

Volltextzugriff (PDF)

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer

Clinical cancer research, 2017-01, Vol.23 (2), p.370-378

2017

Volltextzugriff (PDF)

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Cancer discovery, 2017-12, Vol.7 (12), p.1420-1435

2017

Volltextzugriff (PDF)

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Journal of thoracic oncology, 2021-11, Vol.16 (11), p.1872-1882

2021

Volltextzugriff (PDF)

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2011, Vol.377 (9780), p.1846-1854

2011

Volltextzugriff (PDF)

The biology and management of non-small cell lung cancer

Nature (London), 2018-01, Vol.553 (7689), p.446-454

2018

Volltextzugriff (PDF)

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Journal of thoracic oncology, 2022-03, Vol.17 (3), p.423-433

2022

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Journal of thoracic oncology, 2020-06, Vol.15 (6), p.914-947

2020

Volltextzugriff (PDF)

A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non-Small Cell Lung Cancer

Clinical cancer research, 2014-08, Vol.20 (15), p.3921-3930

2014

Volltextzugriff (PDF)

Immuno-thermal ablations - boosting the anticancer immune response

Journal for Immunotherapy of Cancer, 2017-10, Vol.5 (1), p.78-78, Article 78

2017

Volltextzugriff (PDF)

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

Clinical lung cancer, 2018-07, Vol.19 (4), p.e533-e536

2018

Volltextzugriff (PDF)

1 – 25 von 837

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(789)
Mit Volltextzugriff
(749)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(402)
Life Sciences & Biomedicine
(377)
Humans
(364)
Oncology
(317)
Lung Neoplasms - Drug Therapy
(183)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(162)
Male
(159)
Female
(150)
Biological And Medical Sciences
(144)
Medical Sciences
(140)
Aged
(123)
Middle Aged
(122)
Tumors
(113)
Lung Cancer
(112)
Lung Neoplasms - Pathology
(100)
Adult
(97)
Antineoplastic Agents
(82)
Carcinoma, Non-Small-Cell Lung - Pathology
(81)
Chemotherapy
(77)
Pharmacology. Drug Treatments
(77)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(141)
Clinical Cancer Research
(80)
Journal Of Thoracic Oncology
(80)
Cancer Research
(57)
Clinical Lung Cancer
(35)
Seminars In Oncology
(22)
Journal For Immunotherapy Of Cancer
(20)
The New England Journal Of Medicine
(20)
Cancer
(15)
The Lancet Oncology
(15)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Toward personalized treatment approaches for non-small-cell lung cancer

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC

Lung cancer in the era of precision medicine

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes

Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer

To kill a tumor cell: the potential of proapoptotic receptor agonists

Objective measurement and clinical significance of TILs in non-small cell lung cancer

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

The biology and management of non-small cell lung cancer

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non-Small Cell Lung Cancer

An Epithelial―Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Immuno-thermal ablations - boosting the anticancer immune response

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

Suchergebnisse filtern